Gland Pharma Share Price: 27.7% CAGR in 3 Years as This Injectables Specialist Takes On Sun Pharma, Cipla and Lupin
- November 6, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Gland Pharma Share Price: 27.7% CAGR in 3 Years as This Injectables Specialist Takes On Sun Pharma, Cipla and Lupin
Gland Pharma previous close Rs 3,145.20. 3-year CAGR 27.7%. Up 2.1x since 3 Nov 2023. ROE 9.92%. Market cap Rs 51,934 crore.
Quick Answer
The Gland Pharma share price closed at Rs 3,145.20 on 5 November 2026, a compounded annual return of 27.7% over three years. That compares with Sun Pharmaceutical Industries at 17.0%, Cipla at 5.2% and Lupin at 18.8%. The company has a market cap of Rs 51,934 crore and a P/E of 46.01 against an industry P/E of 38.43.
The Gland Pharma share price offers a useful comparison between a focused sterile injectables company and the large diversified pharma names that dominate the sector. Gland Pharma, a Hyderabad-based maker of generic injectables that listed in late 2020, has compounded faster than three well-known pharma leaders over the last three years.
This article puts numbers on that gap. We calculate the three-year CAGR for Gland Pharma, Sun Pharmaceutical Industries, Cipla and Lupin, and place the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Gland Pharma Share Price Returned in 3 Years?
The Gland Pharma stock closed at Rs 1,510.50 on 3 November 2023 and at Rs 3,145.20 on 5 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 2.08 lakh, which is a CAGR of 27.7%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Gland Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Gland Pharma share price has also been shaped by steady demand for complex injectables in regulated markets such as the United States and Europe, where supply gaps and approvals can matter for revenue.
Gland Pharma vs Sun Pharmaceutical Industries, Cipla and Lupin: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 3 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 5 November 2026.
| Company | Close on 3 Nov 2023 | Previous close (5 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Gland Pharma | Rs 1,510.50 | Rs 3,145.20 | 2.1x | 27.7% |
| Lupin | Rs 1,186.55 | Rs 1,988.00 | 1.7x | 18.8% |
| Sun Pharmaceutical Industries | Rs 1,141.10 | Rs 1,829.00 | 1.6x | 17.0% |
| Cipla | Rs 1,206.35 | Rs 1,404.10 | 1.2x | 5.2% |
The Gland Pharma stock leads the group at 27.7%, followed by Lupin at 18.8%, Sun Pharmaceutical Industries at 17.0% and Cipla at 5.2%. Gland leads the group, with Lupin second, followed by Sun Pharma and Cipla. The three peers are much larger by market cap, so their lower percentage returns came on a far bigger base.
Look at the Gland Pharma share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Rs 4,37,963 crore | 39.86 | 38.43 | 13.79% | 0.04 |
| Cipla | Rs 1,13,243 crore | 39.68 | 38.43 | 8.18% | 0.02 |
| Lupin | Rs 90,887 crore | 17.41 | 38.43 | 21.65% | 0.26 |
| Gland Pharma | Rs 51,934 crore | 46.01 | 38.43 | 9.92% | 0.03 |
By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,37,963 crore, while the Gland Pharma stock stands at Rs 51,934 crore, about 12% of that size. On earnings, Gland Pharma shares trade at a P/E of 46.01 against an industry P/E of 38.43, a premium of about 20%, which signals that the market expects faster earnings growth. Peer multiples are Sun Pharmaceutical Industries at 39.86, Cipla at 39.68 and Lupin at 17.41.
Return on equity is 9.92% for the Gland Pharma stock, which ranks third among the four, and debt to equity stands at 0.03. Trailing EPS is Rs 68.41. Specialist injectable makers often trade at a premium multiple to the sector, so the P/E is best read together with ROE and the pace of earnings growth.
What Is Driving the Gland Pharma Stock?
Gland Pharma develops and manufactures sterile injectables, including vials, ampoules, pre-filled syringes and ophthalmic products. It sells to partners in regulated markets and also markets its own products in several countries.
Injectables are harder to make than tablets because of sterility requirements and regulatory scrutiny. That creates entry barriers, and a company with reliable plants and a strong filing pipeline can benefit from limited competition.
Followers of the Gland Pharma share price usually track new product launches, regulatory inspection outcomes at its plants, the share of contract manufacturing in revenue and margins in the United States.
How the Established Players Stack Up
Sun Pharmaceutical Industries is India’s largest pharma company by market cap, with a presence in generics, specialty and branded products. It compounded at 17.0% a year, on a market cap of Rs 4,37,963 crore and an ROE of 13.79%.
Cipla is a diversified pharma company with strong respiratory and global generics franchises. It compounded at 5.2% a year, on a market cap of Rs 1,13,243 crore and an ROE of 8.18%.
Lupin is a global pharma company with a wide portfolio across generics, branded products and complex formulations. It compounded at 18.8% a year, on a market cap of Rs 90,887 crore and an ROE of 21.65%.
What Should Investors Track Next?
Three things are worth watching on the Gland Pharma share price. First, the outcome of regulatory inspections at its manufacturing sites. Second, the pace of new injectable launches. Third, pricing trends in the United States, its largest export market.
At a P/E of 46, the stock trades above the industry multiple of 38, so earnings delivery matters. A three-year CAGR describes the past, so size any position with that in mind.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Gland Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Gland Pharma share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Gland Pharma share price and compare pharma stocks live.
A Focused Injectables Maker Ahead of the Sector Leaders
The Gland Pharma share price compounded at 27.7% a year over three years, ahead of Lupin at 18.8%, Sun Pharma at 17.0% and Cipla at 5.2%.
Sun Pharma and Cipla bring scale and diversification, Lupin brings the highest ROE among the peers at 21.65%, and Gland brings a specialist injectables play. Matching the choice to your risk appetite matters more than a single number.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Gland Pharma share price today?
Ans. Gland Pharma closed at Rs 3,145.20 on 5 November 2026, according to NSE data. It has a market cap of Rs 51,934 crore and a P/E of 46.01. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Gland Pharma stock?
Ans. Gland Pharma delivered a price CAGR of 27.7% over three years, moving from Rs 1,510.50 on 3 November 2023 to Rs 3,145.20 on 5 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Gland Pharma better than Sun Pharma?
Ans. The Gland stock delivered a higher three-year CAGR at 27.7% than Sun Pharma at 17.0%. Sun Pharma is far larger at Rs 4,37,963 crore and has a higher ROE of 13.79% against 9.92%, with a lower P/E of 39.86. Better depends on whether you prefer growth or scale.
What does Gland Pharma do?
Ans. Gland Pharma is a Hyderabad-based maker of sterile injectables, including vials, ampoules, pre-filled syringes and ophthalmic products, sold to partners and in its own name.
Is the Gland Pharma stock debt free?
Ans. The debt to equity ratio of the Gland Pharma stock is 0.03 and its return on equity is 9.92%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Gland Pharma expensive compared with the industry?
Ans. Gland Pharma trades at a P/E of 46.01 against an industry P/E of 38.43. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Gland Pharma delivered the highest three-year CAGR at 27.7%, followed by Lupin at 18.8%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.